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Summary. The nerve fibre loss, atrophy and injury of diabetic 
peripheral polyneuropathy and their responses to metabolic 
intervention have been studied by morphometric analysis of 
sural nerve biopsies. The magnitudes and sources of intra- 
and inter-individual variation in these morphometric 
measures have not been investigated previously in a syste- 
mat:ic manner. Morphometric parameters of nerve fibre dam- 
age were measured in four separate fascicles from bilateral 
sural nerve specimens obtained post-mortem from 
13 diabetic and 13 non-diabetic subjects. Intra- and inter-in- 
dividual coefficients of variation were computed and corn- 
pared to the magnitude of the differences between normal 
and diabetic subjects. Several morphometric variables 
emerged as highly sensitive and reproducible measures of 
nerve fibre damage suitable for clinical studies of diabetic 
peripheral polyneuropathy. These observations provide a ra- 
tional basis for the design of future clinical trials employing 
morphometric end-points. 
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Diabetic peripheral polyneuropathy is a disease of pro- 
gressive nerve fibre loss, atrophy and injury clinically 
manifest as deteriorating neural function with or without 
accompanying dysaesthetic or paraesthetic symptoms. 
The disease culminates in severe tertiary complications, 
such as insensitivity to pain, anaesthesia, limb deformity, 
ulceration, neuroarthropathy, infection and amputation 
[1]. While sensory loss corresponds with the degree of 
nerve fibre pathology [2], neuropathic symptoms are un- 
reliable indicators of nerve fibre injury [3] and tend to be 
highly varied, transient, and difficult to quantify. Symp- 
toms such as pain appear to reflect processes independent 
of the progressive nerve fibre damage, such as fibre re- 
generation [3] or mechanical foot deformities. Neuropsy- 
chological measurements of sensory loss remain difficult 
to standardize and possess wide day-to-day variation [4, 
5]. Electrophysiological tests such as waveform analysis of 
the evoked muscle or nerve potentials, micro-neurog- 
raphy or single-fibre electromyography [6], that accu- 
rately reflect the functional integrity of nerve fibre popu- 
lations, are not widely available and remain incompletely 
standardized. Readily available, well-standardized diag- 
nostic nerve conduction tests are highly reproducible, but 
their direct translation to nerve fibre damage remains in- 
completely established [1, 7]. Ironically, the brisk respon- 
siveness of these standard tests to abrupt alteration in glu- 
cose control has clouded their morphological and clinical 
interpretability. For example, the small improvements in 
nerve conduction velocity following enhanced glucose 
control [8-15] or administration of an aldose reductase in- 
hibitor (ARI) [16] have been dismissed as reflecting 
changes in nerve biochemistry and/or hydration [17, 18]. 
Therefore, methods that unequivocally quantitate nerve 
fibre damage in diabetic neuropathy are essential to 
define its natural history, pathophysiology, and thera- 
peutic responses, and to develop surrogate measures for 
clinical assessment. 
Sural nerve biopsy is a well-established, safe, although 
invasive diagnostic technique that has been applied in 
clinical trials to morphometrically quantify nerve fibre 
damage of diabetic neuropathy [7,19-21]. The myelinated 
nerve fibre loss, atrophy and injury of diabetic nenropathy 
can be quantified by a combination of light-microscopic 
morphometric assessment ("light morphometry"), cate- 
gorization of teased myelinated nerve fibres ("teased 
fibre analysis"), and by quantitative electron-microscopic 
analysis of the nodal and internodal architecture of myeli- 
nated nerve fibers ("EM morphometry") [21]. Auto- 
mated, computer-driven light morphometry provides 
measures of myelinated fibre density (the number of 
myelinated fibres per unit cross-sectional area), mean 
myelinated fibre size, and myelinated fibre occupancy 
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(the percen tage  of  total  fascicular area comprised of  
myel ina ted  fibres). Individually teased nerve fibres are 
categorized into one  of  eight well-defined groupings,  and 
expressed as percents:  normal  fibres ("% normal") ,  or  fi- 
bres exhibiting nodal  swelling ("% swelling"), pa ranoda l  
demyel inat ion ("% demyel inat ion") ,  pa ranoda l  remyeli-  
nat ion (so-called " intercalated nodes")  ( "%in t e r ca -  
lated"),  segmental  demyel ina t ion  ("% segmental") ,  ex- 
cessive myel in  wrinkling ( "%wr ink led" ) ,  Wallerian 
degenera t ion  ("% Wallerian") ,  or  remyel inat ion/ regener-  
at ion ("% regenera ted")  [21]. The  percents  calculated for 
all but  % regenera ted  exclude regenera ted  fibres so that  
they would  not  dilute the percentages  in o ther  categories. 
E M  m o r p h o m e t r y  quanti tates  an ultrastructural  lesion of  
the node  of  Ranvier  found  in h u m a n  [21] and  animal  [22, 
23] diabetes,  "axo-glial dysjunct ion" (the loss of  the junc- 
t ional complexes  be tween  terminal  myelin loops and the 
axo lemma that  maintain  the structural and functional  in- 
tegrity of  the nodal  appara tus  [24]) ("% axo-glial"); this 
lesion appears  to be a maj or  de te rminant  of  nerve conduc-  
t ion slowing in diabetic rats [24] and patients [25]. 
In  patients with diabetic polyneuropathy ,  m a n y  of  
these parameters  are related to dura t ion and/or  type of  
diabetes and/or  the age of  the  pat ient  [21], and correlate  
with clinical and electrophysiological  responses  to meta-  
boric t r ea tment  [26]. Nerve  m o r p h o m e t r y  has exhibited 
greater  sensitivity and specificity in the neural  response to 
A R I  therapy than convent ional ly  employed  electrophysi-  
ological, neuropsychologica l  or  clinical measures  [27, 28]. 
Highly specific evidence of  nerve fibre repair  and regener-  
at ion and reversal  of  axonal  a t rophy  were  observed  in 
neuropath ic  patients in response  to an A R I  [25, 26]. More-  
over, based  on longitudinal and cross-sectional data,  these 
parameters  appear  to account  for  a major  c o m p o n e n t  of  
the electrophysiological  impai rment  and t rea tment- re-  
sponses in diabetic per ipheral  po lyneuropa thy  [20, 21]. 
Thus, improvemen t  in clinically relevant  morphomet r i c  
parameters  in sural nerve biopsies could be considered 
pr ima facie evidence of  efficacy in the t rea tment  of  
diabetic neuropathy.  Desp i te  these encouraging initial ap- 
plications of  quanti tat ive m o r p h o m e t r y  to clinical trials, 
the design of  future  clinical studies with morphomet r i c  
pr imary end-points  requires formal  evaluat ion of  the 
within-subject and between-subject  variability of  these 
morphomet r i c  measures,  which is the purpose  of  this com- 
municat ion.  
Subjects and methods 
To study the reproducibility and sensitivity of the morphometric 
measures of nerve fibre damage in diabetes, four sural nerve fas- 
cicles (two from the left leg and two from the right leg) were taken 
within 6 h of death from each of 26 subjects, 13 diabetic individuals 
unselected for neuropathy status, and 13 non-diabetic individuals 
free of diseases associated with peripheral neuropathy. The repro- 
ducibility of each of these nerve parameters was assessed by examin- 
hag the variability within and among individuals with diabetes 
(patients) and without diabetes (control subjects). Sensitivity was as- 
sessed by comparing the within- and between-individual variability 
of these parameters in the diabetic patients and in control subjects 
with the group differences of these parameters between diabetic pa- 
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tients and control subjects. The stability of each nerve parameter to 
post-mortem artifact was assessed by comparing three nerve bio- 
psies obtained premortem from living cadaver donors kept on life 
support systems with the contralateral sural nerve obtained from the 
same individuals at autopsy 6 h after death. 
Patient material 
Thirteen consecutive diabetic patients undergoing autopsy at the 
Health Sciences Center in Winnipeg, Manitoba between October 
1987 and June 1988 were included in the study. These nine diabetic 
males and four diabetic females had a mean age of 52.7 + 12.5 years 
(range 2%64 years), and included six subjects who had been diag- 
nosed as having Type i (insulin-dependent) diabetes meUitus and 
seven diagnosed as having Type 2 (non-insulin-dependent) diabetes 
mellitus. Five patients had a recorded clinical diagnosis of diabetic 
neuropathy (four Type 1 and one Type 2) for a mean duration of 
5.4 + 2.6 years (range 1-11 years). Thirteen non-diabetic control 
subjects undergoing autopsy during the same period, eight males 
and five females with a similar mear~ age of 56.8 + 20.0 years (range 
24-81 years) were selected as control subjects. All clinical records 
were scrutinized to exclude patients with disorders or conditions 
other than diabetes associated with peripheral neuropathy. Causes 
of death for diabetic subjects were: seven from cardiovascular dis- 
ease, two from bronchopneumonia, one each from ruptured berry 
aneurysm, peritonitis, ruptured aortic aneurysm, and the sequelae 
from a motor vehicle accident; and for control subjects were: six 
from cardiovascular disease, four from bronchopneumonia, and one 
each from intracerebral haemorrhage, cerebral infarction, and gun 
shot wound. Additionally, three organ-donor subjects whose sural 
nerves were part of a previously-reported series of non-diabetic con- 
trol post-mortem biopsies [21] had had their contralateral sural 
nerves biopsied pre-mortem during organ donation, which were 
analysed to detect post-mortem changes in morphometric parame- 
ters of peripheral nerve. 
Biopsy preparation 
In order to avoid mechanical artifacts, each fascicular sural nerve 
biopsy measuring -3 cm in length was carefully dissected and ex- 
cised from the area posterior to the lateral malleolus, and bisected 
cross-sectionally with crossed razor blades. The two halves were im- 
mediately fixed in 0.1 mol/1 cacodylate-buffered (pH 7.4) 2.5% glu- 
teraldehyde for 24 h at 4~ post-fixed for 2 h at 4~ in 0.1 tool/1 
cacodylate-buffered osmium tetroxide (pH 7.4), and dehydrated in 
graded concentrations of alcohol. One specimen was embedded in 
Epon and semi-thin (0.5 gin) cross-sections were cut and stained 
with tohiidine blue for light microscopic morphometry, and ultra- 
thin cross-and longitudinal-sections were cut and stained with 
aqueous uranyl acetate and lead citrate for EM morphometry. The 
other specimen was used for teased fibre preparation in unpoly- 
merized Epon. The Epon was polymerized after the teased fibres 
were prepared so that individually teased fibres could subsequently 
be examined ultrastructurally. 
Microscopic analysis 
Myelinated nerve fibre damage was quantitated by three micro- 
scopic techniques; light microscopic morphometry of semi~thin cross 
sections of nerve fascicles; electronmicroscopic (EM) examination 
of cross- and longitudinally-sectioned nerve fascicles; and light 
microscopic scoring of single teased nerve fibres. Images for light 
morphometry were digitized and processed with a Cambridge 
Quantamet 10 image analysis system (Olympus Optical Canada 
Ltd., Montreal, Quebec, Canada). Mean myelinated fibre size was 
calculated from an image projected through a 100 x lens to a TV 
monitor and edited to separate abutting myelinated fibres. The num- 
ber and cross-sectional area (including the myelin sheath) of all 
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Fig. 2. Electron micrograph of a node of Ranvier exhibiting axo-glial 
dysjunction. Electronmicroscopic morphometry was employed to 
assess axo-glial dysjunction, expressed as the percentage of terminal 
myelin loops devoid of axo-glial junction (% axo-glial). From each 
serial ultra-thin section through the paranodal region, only inter- 
faces between the axolemma and the terminal myelin loops dis- 
playing clearly visible membranous structure were evaluated. Of 
these, myelin loops devoid of axo-glial junctions (small arrowheads) 
were calculated and expressed as a percentage of total myelin loops. 
The presence of axo-glial junctions between the axolemma and 
myelin loops are indicated by large arrowheads, ml = myelin lamel- 
lae. Mag: x 157,000 
Fig. la ,  b. Representative light-microscopic semi-thin cross-sec- 
tions of sural nerve fascicles from diabetic (a) and non-diabetic (b) 
subjects. The number and cross-sectional area of all myelinated 
fibers within the endoneurial area delineated by the innermost peri- 
neurial lamina (arrows) were calculated. From these calculations, 
myelinated fibre density ( # / m m  2) and fibre occupancy (%) were 
computed. Magnification 145 x 
myelinated fibres in each fascicle were digitized from consecutive 
frames covering the entire fascicular cross section. The endoneurial 
area contained within the innermost perineurial lamella was calcu- 
lated from an image projected by a 4 x lens. From these calculations 
the myelinated fibre density ( # / m m  2) was computed by dividing the 
fibre number by the fascicular area. Myelinated fibre occupancy was 
expressed as the fraction (%) of the endoneurial area occupied by 
myelinated fibres (Fig. 1). 
Interfaces between the terminal myelin loops and the paranodal 
axolemma were examined ultrastructurally for the presence of axo- 
glial junctions in longitudinal ultra-thin sections cut serially through 
the nerve fibre in the region of the node of Ranvier. Only interfaces 
in which the axolemma and the terminal myelin loop were both per- 
pendicular to the plane of the section and thus visible as well-defined 
trilamellar membrane structures were examined (Fig.2). Several 
serial sections were analysed in order to score each myelin-loop-axo- 
lemmal interface in a given node only once for the presence or ab- 
sence of axo-glial junction. Axo-glial junctions were defined as dis- 
crete electron-dense structures -150 A in thickness bridging the 
intercellular space between the terminal myelin loops and the axo- 
lemma in the paranodal region [21, 22, 25]. The percentage of axo- 
glial dysjunction ("% axo-glial") was defined as the percentage of 
myelin loops devoid of axoglial junctions. In each fascicle a mean of 
24.2+0.6 (SEM) paranodal regions with a mean total of 421_+ 
36 (SEM) terminal myelin loops were examined for the absence of 
axo-glial junctions. 
The frequency of myelinated fibres exhibiting defined structural 
abnormalities was determined by screening approximately 100 indi- 
vidually teased myelinated fibres per fascicle. Representative rau- 
dom sampling of fibres was assured by sequentially bisecting the fas- 
cicle in halves, quarters and eights before teasing out single fibres 
from each division. Fibres were teased free of adjacent fibres and 
connective tissue for a length of at least 4-5 mm. An average of 
98 + 2 (SEM) fibres were isolated and examined from each fascicle. 
Each fibre was qualitatively assigned to one of eight well-defined ca- 
tegories (A-H) based on the presence of characteristic structural 
features, and the frequency of each type expressed as percent of non- 
regenerating fibres examined: A: structurally normal fibres 
("%normal") (Fig.3a); B: paranodal swelling ("%swelling") 
defined as a paranodal diameter equal to or greater than 150% of the 
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Fig.3a-d. Teased myelinated fibres exhibiting normal structural 
appearance (a) or abnormalities of the node of Ranvier (b-d). 
Teased fibre analysis was employed to assess the frequency of spe- 
cific microscopically detectable myelinated fibre abnormalities af- 
fecting the node of Ranvier and the internodal segment. The per- 
centage of all teased myelinated fibres exhibiting normal internodal 
segments and normal nodes of Ranvier (a) was computed and ex- 
pressed as % normal. Sequential abnormalities of the node of Ran- 
vier were grouped as either paranodal/nodal swelling (% swelling) 
(b) when the paranodal fibre diameter (arrows) was > 150% of the 
internodal diameter (arrowheads); as paranodal demyelination 
(% demyelination) (e1_3) when the length of the nodal gap (between 
arrows in el) was _> the fibre diameter (arrowheads); or as remyeli- 
nated (intercalated) nodes (% intercalated) characterized by short, 
thinly-myelinated internodes intercalated between two normal in- 
ternodes (d). The same type of nodal change was often encountered 
in subsequent nodes of the same fibre e. g. paranodal demyelination 
in e 2 3 
internodal diameter (Fig. 3 b); C: paranodal demyelination ("% de- 
myelination"), defined as a nodal gap equal to or greater in distance 
than the internodal diameter (Fig.3c); D: excessive myelin wrin- 
lding ("% wrinkled"), defined as intact but "corrugated" inter- 
nodal myelin with great variations in diameter whereby the smal- 
lest diameter is equal to or less than 50% of the greatest 
diameter (Fig.4a); E: intercalated (remyelinated) nodes, ("% in- 
tercalated"), characterized by a short and thinly myelinated segment 
intercalated between two normal internodal segments (Fig.3d); 
F: Watlerian degeneration ("% Wallerian"), characterized by frag- 
mentation of the myelinated fibre into myelin ovoids and balls in 
several consecutive internodes (Fig.4b); G: segmental demyeli- 
nation ("% segmental"), defined as fragmentation of myelin within 
one or more internodal segments (Fig. 4c); H: regenerated and/or 
remyelinated fibres, ("% regenerated"), characterized by short 
thinly myelinated consecutive internodes and defined as having 
an internodal length equal to or shorter than 50% of that which 
would be expected for fibre diameter (Fig.4d). Fibres exhibiting 
more than one abnormality were scored according to the most 
severe change (with B < C < E < D < G < F) except for regenerated 
fibres (H) which were interpreted to reflect a reparative state. The 
fibres classified A-G were expressed as a percentage of total non- 
regenerated fibres (A + B + C + D + E + F + G = 100%) to eliminate 
a possible dilutional effect of newly-regenerated fibres on the 
frequency of otherwise normal or abnormal fibres [21, 25, 26]. This 
adjustment becomes quantitatively important in studies of dia- 
betic neuropathy that include treated patients with active rege- 
neration [26]. For the regenerated fibres, the percent was compu- 
ted from the total number of fibres including regenerated fibres [25, 
26]. 
The nerve fibre damage from diabetes identified by these indi- 
vidual morphometric measures was aggregated into three compo- 
nents, fibre loss, atrophy and fibre injury. Fibre loss was defined by 
the measurement of fibre density (#  flbres/mm z) which remains 
relatively independent of normal variation in fascicular number and 
size and level of branching in human sural nerve. Fibre atrophy was 
assessed by % wrinkled which correlates closely with the more direct 
measures of nerve fibre atrophy such as myelin/axon ratio and inter- 
nodal-length:fibre diameter ratio [25] support this approach. Fibre 
injury was assessed by % normal, (a measure of uninjured fibres) 
and % swelling, % demyelination, % intercalated, % segmental, and 
% Wallerian. Based on these considerations, an index of normality 
was computed as the product of the percent normal fibres and fibre 
density, since this index would represent the number or density of 
structurally normal nerve fibres. This composite index of normality 
reflects nerve fibre loss (the reduction in fibre density), atrophy (the 
reduction in % normal due to the increase in % wrinkled), and injury 
(the reduction in % normal accounted for by changes in % swelling, 
% demyelinated, % intercalated, % Wallerian or % segmental) as 
well as recording the density or number of structurally normal nerve 
fibres at the light microscopic level. Regenerative activity was as- 
sessed as % regenerated [21]. Because the subjects in this study were 
not undergoing treatment to increase fibre regeneration, mean fibre 
size was considered to be a combined measurement of fibre atrophy 
and/or the selective loss of larger nerve fibres [21] (in contradistinc- 
tion to patients undergoing a metabolic intervention associated with 
increased fibre regeneration, since newly-regenerated fibres are 
smaller than the fibres that they have replaced [26]). 
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Statistical analysis 
The means, SD and ranges of the morphometric variables were com- 
puted separately for the diabetic and for the non-diabetic subjects. 
For technical reasons there were values for % axo-glial for only 
eleven of the diabetic subjects. The Behrens-Fisher two-sample 
t-test which does not assume equality of variances of the two groups 
was used to compare the group means and Levene's test was used to 
test the equality of the two variances. Two-sided p-values are re- 
ported throughout. No correction was made for the number of tests 
being performed. Due to the small sample sizes, subjects with Type 1 
or Type 2 diabetes, or with or without clinically-overt neuropathy, 
were not analysed separately. All data are shown as + SD unless 
otherwise noted. 
The components of variance were estimated for each parameter 
separately for diabetic and for non-diabetic subjects using a two-way 
analysis-of-variance (ANOVA) with fascicle (two per side) and side 
(left vs right leg) as factors. In this case non-significance would indi- 
cate that there was no systemic difference between the two fascicles 
on the same side or between the two sides, and would be consistent 
with the widely-held belief that diabetes-associated nerve damage is 
in general a diffuse symmetrical process. The components of vari- 
ance attributed to fascicle, side, subject and error were re-expressed 
in the tables as coefficients of variations (expressed as %) by first 
taking their square roots (to obtain standard deviations) and then 
dividing by the mean of the parameter for the group. Then the anal- 
ysis of variance was repeated using the data from all 26 subjects with 
the inclusion of a factor to represent the two groups of subjects. 
The association between the two fascicles on each side or be- 
tween the two sides were computed as intraclass correlations which 
are measures of linear correlation when the two variables are inter- 
changeable (i. e., the results for the two fascicles on each side could 
be interchanged since it is arbitrary which is labelled first and which 
is second). 
Results  
Fig.4a-d. Teased myelinated fibres exhibiting abnormal internodal 
structure. Teased fibre analysis was employed to assess the fre- 
quency of specific abnormalities of the internode, such as excessive 
myelin wrinkling (% wrinkled) (a), indicative of axonal atrophy ap- 
pearing as corrugated "wrinkled" myelin sheaths such that the smal- 
lest fibre diameter (arrows) is < 50% of the greatest diameter 
(arrowheads). Wallerian degeneration (%Wallerian) (bl_3) is 
characterized by myelin fragmentation in consecutive internodes. 
Segmental demyelination (% segmental) (c) is characterized by de- 
myelination within the internodal segment in contrast to paranodal 
demyelination (compare with Figure3cl_3). Regenerated fibres 
(% regenerated) (d1_2) display short evenly-spaced consecutive in- 
ternodes (between arrows) with an internodal length _< 50% of that 
expected for the fibre diameter 
Post-rnortem stability of  nerve morphometry (Table 1) 
Compar i son  of morphomet r i c  pa ramete r s  in cont ra la tera l  
sural  nerve  specimens  ob ta ined  pre-  and  pos t -mor t em 
f rom three  non-d iabe t i c  cadaveric organ  donors  revealed  
no  systematic a l tera t ion in the first 6 h after dea th  
(Table 1). 
Table 1. Pre- and post-mortem sural nerve morphometry in three 
normal control subjects 
Variable Subject I Subject 2 Subject 3 
Pre Post Pre Post Pre Post 
Fibre size (gm 2) 34.1 35.6 3 4 . 5  3 3 . 4  40.1  41.4 
Fibre density (# /mm 2) 7,253 7,155 8,267 8,483 8,981 9,144 
Fibre occupancy (%) 26.2 2 5 . 5  2 7 . 9  2 8 . 3  37.1  37.9 
Index of normality 6,847 6,640 7,953 8,033 8,585 8,669 
% Axo-glial 4.9 5.4 6.9 8.3 4.1 3.8 
% Normal 94.4 9 2 , 8  9 6 . 2  9 4 . 7  95 .6  94.8 
% Swelling 0.0 0.9 0.0 0.0 0.0 0.0 
% Demyelination 0.8 0.0 0.0 0.7 0.0 0.0 
% Wrinkled 1.7 0.9 1.3 1.3 0.7 1.2 
% Intercalated 0.0 0.0 0.7 0.0 1.5 0.0 
% Wallerian 0.8 0.9 0.0 1.3 0.7 0.6 
% Segmental 0.0 0.9 0.0 1.3 0.7 0.6 
% Regenerated 1.7 2.8 1.3 0.7 0.7 2:5 
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Effect of diabetes on nerve fibre loss, atrophy and injury 
(Table 2) 
Means, SD and ranges for morphometr ic  variables are 
presented in Table 2 for the diabetic cases and the non- 
diabetic control subjects. The p-values of the Behrens- 
Fisher t-test to compare  the two group means and of 
Levene's  test for the equality of the two variances are 
presented in Table 2. Attr ibutes of nerve fibre damage 
were more  evident in diabetic cases compared  to non- 
diabetic control subjects. Fibre density, a measure of fibre 
loss, and mean  fibre size and fibre occupancy, reflective of 
fibre loss and atrophy, had larger means in normal  control 
subjects than in the diabetic cases but  the diabetic cases 
exhibited larger variances. No differences in areas of 
examined fascicles could be  demonstra ted between fas- 
cicles of the same side, or between sides, or between con- 
trol subjects and diabetic cases (Table 3). Index of nor- 
mality and % normal  were also greater  in normal  control 
subjects than in the diabetic cases. The frequencies of four 
categories of abnormal  nerve fibres (% swelling, % de- 
myelinated, % wrinkled and % Wallerian) were greater in 
diabetic cases than in control subjects. Thus, sural nerve 
samples f rom diabetic autopsy cases unselected for clini- 
cal neuropathy demonstra ted  significant evidence of 
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nerve fibre loss, atrophy and injury compared  to control 
subjects. 
The nerve-fibre damage as measured by differences 
between the diabetic and non-diabetic subjects in this 
study were qualitatively similar (i. e. differ in the same di- 
rection) to those previously reported for a somewhat  
younger group of diabetic patients with diagnosed poly- 
neuropathy compared  to their age-matched control sub- 
jects [29]. In the present  study, the difference between the 
diabetic and non-diabetic subjects was somewhat  less than 
that reported in the previous study for many  of the indi- 
vidual morphometr ic  parameters  (e. g. fibre density, % 
wrinkled, % normal  and % axo-glial) [21], although the 
reduction in mean fibre size in the diabetic subjects was 
proport ionately greater in the present  study. This gener- 
ally milder degree of nerve damage is in keeping with the 
fact that the present  cases were unselected for the 
presence of diagnosed diabetic neuropathy. 
Effect of diabetes on the components of variation 
of morphometric variables 
The primary goal of this study was to analyse the compo- 
nents of variation of the morphometr ic  attributes of fibre 
injury in diabetic neuropathy (i. e. how large was the in- 
Table 2. Descriptive statistics for each morphometric variable by group 
Variable Group 1 Mean SD Range t-test 2 Equ of V a r  3 
Fibre size (gin?) Control 35.0 6.5 23.1-51.0 0.008 0.004 
Diabetic 25.8 10.1 11.3M2.3 
Fibre occupancy (%) Control 26.6 6.7 13.3-39.9 0.004 0.004 
Diabetic 13.7 12.5 0.1-35.4 
Fibre density ( #/ram 2) Control 7691 1857 5038-11847 0.006 0.03 
Diabetic 4561 3180 34-9892 
Index of normality Control 6285 1721 3900-9270 0.001 0.17 
Diabetic 3140 2464 22-7540 
% Axo-glial Control 11.71 3.04 5.1-17.9 0.022 0.009 
Diabetic 20.91 11.39 6.2-48.0 
% Normal Control 81.64 9.86 50.9-98.0 0.001 0.32 
Diabetic 63.33 15.84 29.4-82.7 
% Swelling Control 1.84 1.39 0-5.3 0.004 0.07 
Diabetic 4.40 2.98 0-15.4 
% Demyelination Control 3.23 2.25 0-10.6 0.001 0.003 
Diabetic 8.22 4.13 1.5-20.0 
% Wrinkled Control 6.44 5.65 0-21.2 0.021 0.13 
Diabetic 14.34 10.87 0-46.6 
% Intercalated Control 5.46 3.99 0-17.5 0.23 0.93 
Diabetic 6.89 4.04 0-22.7 
% Wallerian Control 0.86 1.36 0-4.8 0.033 0.040 
Diabetic 2.51 3.84 0-20.0 
% Segmental Control 0.53 1.20 0-7.1 0.30 0.41 
Diabetic 0.32 0.75 0-2.7 
% Regenerated Control 0.47 1.04 0-5.6 0.13 0.04 
Diabetic 3.19 6.93 0-35.3 
1 There are 13 subjects per group, except that "% axo-glial" is avail- 
able for only 11 diabetic subjects. 
The column "t-test" contains p-values for the two-sample (Beh- 
tens-Fisher) t-test, and indicates the probability that the means of 
the control and diabetic groups could have differed by chance alone. 
3 The column "equ of var" contains p-values for the Levene-'s test of 
equality of variances and indicates the probability that the variances 
of the control and diabetic groups could have differed by chance 
alone. All p-values are two-tailed 
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Table 3. Mean fascicular areas of the first and second fascicles of the left and right sural nerves from control subjects and diabetic patients a 
Fascicular area (ram 2) 
Left i Left 2 Right 3 Right 2 
Control subjects 








Group (n = 52) mean: 
Range: 
Diabetic patients 
Group (n = 52) mean: 
Range: 
0.0576 + 0.0098 0.0618 + 0.0116 0.0641 + 0.0145 0.0596 __+ 0.0147 
0.0435- 0.0697 0.0552- 0.0898 0.0409- 0.0818 0.0432- 0.0816 
0.0623 + 0.0170 0.0616 __+ 0.0102 0.0602 + 0.0152 0.0590 __+ 0.0128 
0.0435- 0.0979 0.0435- 0.0784 0.0348- 0.0833 0.0341- 0.0851 
0.0605 _+ 0.0135 
0.0409- 0.0898 
0.0616 + 0.0144 
0.0341- 0.0979 
a No significant differences could be obtained between fascicles of the same side, or between fascicles of.the two sides, or between fascicles from 
control subjects and diabetic patients 
herent  variation of the measurements and how these 
measures differed as a function of fascicle and side relative 
to differences between individuals). The components of 
variance were estimated from a two-way repeated 
measures analysis of variance (ANOVA) model fitted to 
the data for each variable where the factors were fascicle 
and side. If all the factors were assumed to be random ef- 
fects, it was possible to estimate the variation due to the 
three factors. The estimates of the components of vari- 
ance expressed as coefficients of variation (CV) are 
shown in Table 4. 
Since each teased fibre frequency was based on count- 
ing the type of fibre abnormality among the N100 fibres 
examined, it was possible to compute the theoretical vari- 
ance due to counting a random set of fibres, which would 
represent a lower limit to the technical variation of the 
method. This lower limit for the standard deviation (SD) 
representing the technical error  of the percent  counts was 
approximated by the formula for a binomial variate, 
i. e., SD = 100[p(1-p)/n] m and CV(%) = 100[(1-p)/(np)] la 
where p is the proport ion of the fibres and n is the total 
number  of fibres counted. For  example, the mean of 
% normal was 72.5%, with theoretical SD of 4.5% and a 
CV-err of 6.2%. Since 6.2% is greater than the CV-err in 
Table 4, the variability was explained by the random pro- 
cess of choosing fibres to be counted. Other  possible com- 
ponents of residual error would include heterogeneity 
within fascicles, etc. 
A reproducible observation in an observation for which 
CV-subj > > CV-err, CV-fasc and CV-side. This pattern (a 
ratio of 5:1 for CV-subj divided by the largest of CV-err, CV- 
fasc and CV-side) was observed for fibre size, density and 
occupancy, % axo-glial, % normal and index of normality. 
% Wrinkled had a ratio of 2:1 and other variables had ratios 
less than 1:1. For  untreated diabetic subjects, the ratio for 
% regeneration was approximately 2:1, although a large 
change (300%) in % regeneration has been reported in 
diabetic subjects as a result of metabolic intervention, in 
which case this measure would also become highly repro- 
ducible due to the large anticipated increase [26]. 
As part of the results of the ANOVA, the effects of side 
and fascicle and their interaction were tested. Since these 
tests were performed for each line of Table 4, a total of 
117 tests were computed. Of these tests, only one test was 
significant at the 1% level of significance and another five 
at the 5% level; this is what would be expected by chance 
alone when this number of tests are performed. 
Another  way of evaluating the consistency of the re- 
sults between fascicles and/or sides is to compute the 
correlation between sides or between fascicles. The intra- 
class correlation coefficients are presented in Table 5. A 
high correlation implies good agreement between the two 
fascicles or sides. Zero indicates that the minimum corre- 
lation was negative. The variables fibre size, fibre occu- 
pancy, fibre density, % axo-glial, % normal and index of 
normality were relatively consistent between fascicles and 
between sides, and thus constituted informative parame- 
ters in the sense that they reflected the degree of fibre 
damage for an individual subject. In contrast, fibre ca- 
tegories that appeared infrequently had low correlations, 
i. e. exhibited poor  agreement between biopsies. These re- 
sults supported those of the ANOVA. By these criteria, 
six parameters,  fibre size, fibre occupancy, fibre density, 
% axo-glial, % normal and index of normality, constituted 
logical candidates for end-points in cross-sectional or lon- 
gitudinal studies of peripheral nerve damage in diabetes. 
In addition, % regenerated constituted an informative 
parameter  under conditions when regeneration is sub- 
stantially increased, for example by specific intervention 
such as A RI  therapy [26]. 
Discussion 
These studies were not intended to explore the fundamen- 
tal morphometr ic  basis of diabetic neuropathy. Rather  
they employed autopsy material as a convenient model in 
which to examine the extent to which sampling errors 
and/or intrinsic variability might limit the sensitivity and 
specificity of fascicular sural nerve biopsies as quantita- 
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Table 4. Coefficients of variation of the morphometric measure- 
ments by group 
Variable Group a Mean CV- CV- CV- CV- 
Err b Fasc b Side b Betw b 
Fibre size (~tm 2) All 30.40 10% 4% 0% 30% 
Control 35.04 6% 5% 0% 17% 
Diabetic 25.75 15% 0% 0% 37% 
Fibre density All 6126 9% 0% 0% 48% 
(# /mm 2) Control 7691 8% 0% 0% 23% 
Diabetic 4561 11% 3% 0% 69% 
Fibre occupancy All 20.15 9% 5% 4% 58% 
(%) Control 26.59 7% 4% 3% 23% 
Diabetic 1 3 . 7 2  11% 4% 4% 90% 
Indexofnormality All 4712 11% 3% 0% 55% 
Control 6285 10% 2% 0% 26% 
Diabetic 3140 13% 5% 0% 77% 
% Axo-glial All 15.93 10% 3% 8% 56% 
Control 11.71 12% 0% 0% 24% 
Diabetic 20.91 9% 5% 9% 53% 
% Normal All 72.48 4% 3% 0% 21% 
Control 81.64 4% 3% 0% 11% 
Diabetic 63.33 5% 3% 2% 23% 
% Swelling All 3.12 55% 0% 0% 67% 
Control 1.84 63% 34% 0% 22% 
Diabetic 4.40 49% 0% 0% 52% 
% Demyelination All 5.72 48% 0% 13% 56% 
Control 3.23 55% 0% 38% 26% 
Diabetic 8.22 42% 0% 0% 33% 
% Wrinkled All 10.39 35% 26% 0% 80% 
Control 6.44 42% 0% 14% 77% 
Diabetic 1 4 . 3 4  30% 28% 0% 64% 
% Intercalated All 6.17 45% 19% 22% 38% 
Control 5.46 47% 24% 35% 35% 
Diabetic 6.89 43% 15% 4% 38% 
% Wallerian All 1.69 92% 154% 0% 0% 
Control 0.86 99% 90% 28% 31% 
Diabetic 2.51 80% 143% 0% 0% 
% Segmental All 0.42 195% 104% 35% 0% 
Control 0.53 195% 118% 0% 0% 
Diabetic 0.32 173% 0% 181% 0% 
%Regenerated All 1.83 83% 82% 108% 219% 
Control 0.47 197% 88% 0% 80% 
Diabetic 3.19 61% 65% 89% 170% 
a "All" refers to the combined total of 13 control and 13 diabetic sub- 
jects, except that data on % axo-glial was available for only 11 of the 
13 diabetic subjects. 
b CV's are expressed as percentages of the mean 
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Table 5. Intraclass correlation between ipsilateral fascicles and be- 
tween sides for all subjects 
Variable Within sides Between sides 
Left Right 
Fibre size 0.90 0.85 0.96 
Fibre density 0.97 0.95 0.99 
Fibre occupancy 0.97 0.96 0.97 
Index of normality 0.96 0.95 0.99 
% Axo-glial 0.97 0.95 0.96 
% Normal 0.93 0.94 0.95 
% Swelfing 0.58 0.68 0.79 
% Demyelination 0.67 0.66 0.69 
% Wrinkled 0.66 0.84 0.92 
% Intercalated 0.13 0.59 0.39 
% Wallerian 0 0 0.70 
% Segmental 0.02 0.19 0 
% Regenerated 0.94 0.35 0.68 
t ive ind ica tors  of  the  sever i ty  of  sura l  nerve  d a m a g e  in 
cl inical  s tudies  of  d iabe t i c  neuropa thy .  These  obse rva -  
t ions d e m o n s t r a t e  tha t  ce r ta in  m o r p h o l o g i c a l  ha l lmarks  
o f  ne rve  f ibre  d a m a g e  in d i abe te s  and  in d iabe t i c  neu-  
r o p a t h y  can  be  re l i ab ly  assessed and  q u a n t i t a t e d  in single 
samples  of  sura l  nerve ,  and  tha t  the  sampl ing  e r rors  a re  
smal l  c o m p a r e d  to  the  changes  p r o d u c e d  by  d iabetes .  
T h e y  also suggest  tha t  the  m o r p h o m e t r i c  da ta  o b t a i n e d  
f rom a single fascicle a re  r e p r e s e n t a t i v e  of  those  for  the  
whole  sural  nerve ,  and  tha t  the  va r i a t i on  b e t w e e n  con t ra -  
l a te ra l  sura l  nerves  is small .  A l t h o u g h  these  s tudies  fo- 
cused  on  sural  nerve  samples  f rom cadavers ,  t hey  a re  
read i ly  e x t r a p o l a t e d  to  sura l  ne rve  b iops ies  f rom living 
pa t ien t s  be c a use  the  abno rma l i t i e s  a s soc ia t ed  wi th  
d iabe tes  a re  qua l i t a t ive ly  s imi lar  to  those  in nerve  b iop -  
sies f rom n e u r o p a t h i c  d iabe t ic  pa t ien ts ,  and  b e c a u s e  these  
m o r p h o m e t r i c  p a r a m e t e r s  inc luding  % axo-gl ia l  and  
% wr ink l ed  a re  s tab le  for  at leas t  6 h a f te r  dea th  [21]. 
Howeve r ,  be c a use  of  the  invas ive  na tu re  of  the  sural  ne rve  
b iopsy  p r o c e d u r e  and  a smal l  r isk of  pers i s t ing  pa in  o r  
pa r a e s the s i a  pos t -opera t ive ly ,  it  should  no t  be  r e g a r d e d  as 
a rou t ine  d iagnos t ic  t echn ique ,  bu t  mere ly  be  l imi ted  to  
de t a i l ed  assessments  of  drug  eff icacy in cl inical  t r ials  and  
to  c o m p r e h e n s i v e  we l l -des igned  cross-sec t iona l  cl inical  
inves t iga t ions  i n t e n d e d  to exp lo re  the  na tu ra l  h is tory  of  
the  disease.  F u r t h e r m o r e  f ibre  dens i ty  and  occupancy  can 
be  r e g a r d e d  as re l i ab le  m e a s u r e s  of  f ibre  loss, s ince fas- 
c icular  a r ea  f rom which  these  measu re s  a re  pa r t i a l ly  
der ived ,  was u n c h a n g e d  b e t w e e n  fascicles of  the  same  
Table 6. Estimates of coefficients of variation (CV's) for the computation of sample sizes for clinical trials in diabetic subj ects employing sural 
nerve morphometry 
Variable Mean CVdiff-within individuals CVdiff-betw individuals CVdiff-betw/ Predicted Observed 
CVdiff-within SD SD" 
Fibre density ( # /mm 2) 4561 16% 100% 6.2 730 1220 
Index of normality 3140 20% 112% 5.7 628 784 
% Axo-glial 21 19% 80% 4.1 4.0 6.1 
% Normal 63 9% 35% 4.0 5.7 8.5 
% Wrinkled 14 58% 122% 2.1 8.1 7.7 
% Regenerated 3.2 178% 348% 1.9 5.7 5.7 
"Based on published aldose reductase inhibitor trial using serial nerve biopsies [26] 
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side, between sides or between control subjects and 
diabetic cases. Thus, reliable estimates of nerve fibre loss 
(fibre density and occupancy), atrophy (mean fibre size, 
% wrinkling and fibre occupancy), injury (% normal and 
% axo-glial), and overall damage (index of normality) can 
be used to measure severity, progression and/or treatment 
response in patients with diabetes and/or diabetic neuro- 
pathy. Furthermore, nerve fibre regeneration can be re- 
liably assessed when % regeneration is increased in re- 
sponse to therapy [26]. 
The estimates of the CV's can be used to define the 
sample size of a study of the natural progression of the dis- 
ease. In such a study the CV's represent the anticipated 
variability between two biopsies when no changes are ex- 
pected. The CV of a difference between two biopsies 
within the same individual at different time points (CV 
diff-within) is computed as the square root of 2(CV- 
err2+ CV-fasc2+ CV-side2). The CV of a difference be- 
tween two individuals (CV diff-betw) would be computed 
similarly but would also include in the summation the CV- 
subj z. 
To show a change of one SD in paired biopsies from the 
same individual at different time points when using a 
paired t-test (i.e., a change equal to CV dill-within), 
10 subjects are necessary to achieve 80% power using a 
two-sided 5% level of significance. To achieve the same 
power using a case-control design where pairs of subjects 
at presumably the same stage of disease would be ran- 
domly assigned to undergo biopsy at one of two time 
points would require a change equal to the CV diff-betw 
to achieve the same power. The squares of the ratios CV 
diff-betw and CV diff-within represent the increase in 
sample size that would be needed if a case-control study 
design was used in place of a dual biopsy design. That is, 
the sample size would have to increase greatly if the same 
subjects are not biopsied twice to obtain longitudinal data 
reflecting disease progression. 
Many studies require the comparison of a treatment to 
a placebo. Since not all subjects will react similarly to the 
treatment, it is necessary to include the variability of re- 
sponses to the treatment in the calculation of the sample 
size. Although differences between the two biopsies from 
each subject are computed, the comparison of the dif- 
ferences between the two groups involves a between-sub- 
ject component. When the SD obtained for the difference 
in the treated group (10 subjects) in a previous double bi- 
opsy study [26] is compared with the predicted SD-within 
from this study, the two SD's are very similar for several of 
the parameters, but for others there is a ratio of 1.5-2.0. 
For these parameters, it is necessary to adjust the sample 
size of the planned experiment to allow for this increased 
variability which may be due to a differential response to 
the treatment. 
The design of therapeutic trials in complex chronic dis- 
eases is often severely limited by disease heterogeneity, 
chronicity, and irreversibility, as well as the lack of objec- 
tive, quantitative, sensitive and reproducible measures to 
assess disease progression. Although a consensus con- 
ference suggested a combination of clinical and objective 
tests to diagnose and stage diabetic peripheral neuropathy 
[29], the sensitivity and reproducibility of this staging 
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paradigm for therapeutic intervention trials was not ad- 
dressed. Indeed, using acceptable norms of reproduci- 
bility [30], and minimal estimates for clinically significant 
changes [31] for vibratory perception threshold measure- 
ments, it has been estimated that hundreds of patients per 
group would be required to demonstrate with acceptable 
power a minimally clinically significant vibratory percep- 
tion threshold response to metabolic intervention over a 
12-month treatment trial [R SOnksen, personal communi- 
cation]. Although smaller sample sizes would possess ade- 
quate statistical power to document corresponding de- 
grees of improvement in nerve conduction velocity [31, 
R S6nksen, personal communication], the clinical rele- 
vance of such demonstrations [16] in the past has been 
questioned. In contrast, nerve fibre damage defines 
diabetic neuropathy, clearly distinguishing diabetic pa- 
tients with neuropathy from non-diabetic subjects and 
from non-neuropathic diabetic patients [32]. Nerve fibre 
damage correlates with clinical neuropathic status and 
nerve function in diabetic neuropathy [3, 7, 25, 26], and is 
generally accepted to be the underlying cause of the com- 
mon clinical syndromes of diabetic peripheral polyneuro- 
pathy [1, 3, 7,19, 20, 21, 25, 26, 32]; hence its overall clinical 
relevance is unquestioned. This report demonstrates that 
the maj or morphometric parameters of the three cardinal 
elements of nerve fibre damage in diabetes, nerve fibre 
loss, atrophy and injury, can be reproducibly and sensi- 
tively measured in sural nerve biopsies from small num- 
bers of subjects, suggesting that quantitative morpho- 
metric analysis of sural nerve biopsies constitutes a 
sensitive, reproducible and informative end-point for 
clinical studies of diabetic neuropathy. 
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